Opinion

The studio model: how film industry practices can boost pharmaceutical creativity

FDA’s management of drug and device safety enters GAO’s biennial watch list

It has been said that one should never miss an opportunity to make the most of a crisis. The steady stream of headlines announcing staff cuts, delays in drug approvals and a narrowing of R&D focus for pharmaceutical and biotech companies indicate there will be no shortage of opportunities in 2009.

‘Ultra-orphan’ diseases will alter the specialty distribution process